Corcept Therapeutics (NASDAQ:CORT) Price Target Cut to $99.00 by Analysts at Canaccord Genuity Group

Corcept Therapeutics (NASDAQ:CORT) had its price objective lowered by Canaccord Genuity Group from $140.00 to $99.00 in a research note published on Friday morning, MarketBeat Ratings reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on the stock. HC Wainwright decreased their price target on shares of Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday. Wall Street Zen lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a research report on Wednesday. Finally, UBS Group started coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $80.83.

Corcept Therapeutics Trading Up 9.8%

CORT opened at $38.20 on Friday. The business has a fifty day moving average price of $76.45 and a 200 day moving average price of $74.78. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. Corcept Therapeutics has a 12 month low of $32.99 and a 12 month high of $117.33. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of 43.41 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.02). Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The company had revenue of $207.64 million during the quarter, compared to analysts’ expectations of $223.78 million. During the same quarter in the previous year, the business posted $0.41 EPS. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. Sell-side analysts expect that Corcept Therapeutics will post 1.36 earnings per share for the current fiscal year.

Insider Activity

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.53, for a total transaction of $397,650.00. Following the completion of the transaction, the insider owned 10,277 shares in the company, valued at approximately $817,329.81. This represents a 32.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $89.94, for a total transaction of $1,798,800.00. Following the completion of the sale, the insider directly owned 5,287 shares in the company, valued at approximately $475,512.78. The trade was a 79.09% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 196,700 shares of company stock valued at $15,474,198. 20.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Abacus FCF Advisors LLC purchased a new stake in Corcept Therapeutics during the 3rd quarter worth about $3,238,000. Pacer Advisors Inc. lifted its holdings in Corcept Therapeutics by 6,796.7% in the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after purchasing an additional 384,896 shares in the last quarter. Cerity Partners LLC boosted its stake in shares of Corcept Therapeutics by 21.4% during the 2nd quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock worth $54,800,000 after purchasing an additional 131,799 shares during the last quarter. Ellsworth Advisors LLC purchased a new stake in shares of Corcept Therapeutics during the third quarter worth about $769,000. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Corcept Therapeutics by 154.1% during the second quarter. State Board of Administration of Florida Retirement System now owns 58,596 shares of the biotechnology company’s stock worth $4,301,000 after buying an additional 35,539 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord cut its price target from $140 to $99 but kept a “buy” rating, signaling some sell‑side conviction that there is still meaningful upside from current levels if the company resolves regulatory issues or demonstrates efficacy in follow‑up data. Benzinga
• Neutral Sentiment: Options implied volatility has surged, reflecting elevated uncertainty and trader interest; that can amplify price moves (both rebounds and further declines) and is likely contributing to today’s bounce as short squeezes / gamma flows unwind. Implied Volatility Surging for Corcept Stock Options
• Neutral Sentiment: Unusually large options trading was reported around CORT, consistent with the volatility spike; that activity can produce sharp intraday rallies even when fundamentals remain unchanged. Monitor open interest and large‑block trades for clues to whether the move is technical/speculative versus a change in fundamentals. Corcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)
• Negative Sentiment: The FDA issued a Complete Response Letter for relacorilant, saying the agency needs additional evidence of effectiveness for treating hypercortisolism (Cushing’s). That CRL drove the prior ~50%+ collapse in the share price and is the core fundamental headwind — approval now requires more data or discussions with the FDA that could delay or derail the drug’s U.S. launch. Corcept Receives Complete Response Letter for Relacorilant
• Negative Sentiment: Multiple outlets summarize the practical impact: analysts and investors marked down valuations and the stock hit new lows after the FDA decision — this is an ongoing risk to revenue/cash‑flow forecasts if relacorilant was a key growth driver. Corcept Tanks on FDA’s CRL to Relacorilant NDA in Hypercortisolism
• Negative Sentiment: Kaplan Fox has alerted investors to a possible securities‑law investigation into Corcept, which can prolong downside pressure and raise potential legal/settlement expenses. This increases headline risk even if operational issues are later resolved. Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (CORT) to an Investigation of Possible Securities Law Violations

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.